Mildronate (Meldonium Dihydrate)

Meldonium, the active ingredient in Mildronate, is a metabolic modulator presented as an oral dosage form for oral administration. It is indicated for patients with ischemic heart disease, angina pectoris, heart failure, and peripheral arterial disease, where it aims to improve myocardial energy efficiency under reduced oxygen supply.

GNH USA supplies Mildronate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU market standards.

Mildronate acts on cardiac energy metabolism and is employed in several cardiovascular conditions.

- Ischemic heart disease: improves myocardial efficiency and reduces symptoms of reduced blood flow. - Angina pectoris: lessens chest pain episodes by supporting cardiac energy production. - Heart failure: helps maintain cardiac output by shifting energy substrate utilization. - Peripheral arterial disease: aids tissue perfusion by enhancing cellular metabolism in ischemic limbs.

Mildronate is generally well tolerated, but adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: abdominal pain or dyspepsia. - Insomnia: difficulty initiating sleep. - Fatigue: feeling of reduced energy.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm requiring medical evaluation. - Severe hypotension: marked drop in blood pressure. - Allergic reaction: rash, itching, or swelling. - Hepatic enzyme elevation: abnormal liver function tests. - Severe skin rash: Stevens‑Johnson‑like manifestations. - Thrombocytopenia: low platelet count with bleeding risk.

Before initiating therapy, clinicians should consider several safety aspects.

- Cardiac assessment: evaluate baseline heart function and ischemic status. - Renal monitoring: adjust use in patients with impaired kidney function. - Hepatic review: avoid in severe liver disease until safety is established. - Concomitant drugs: assess interactions with other cardiovascular agents. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as data are limited. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mildronate may affect or be affected by other medications.

Major Interactions (Avoid): - Other carnitine synthesis inhibitors: additive metabolic effects. - Strong CYP450 inducers: may reduce Meldonium plasma levels. - Anticoagulants: increased risk of bleeding. - Anti‑arrhythmic agents: potential for enhanced cardiac rhythm disturbances. - High‑dose statins: possible increased muscle toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: monitor heart rate and blood pressure. - Nitrates: observe for excessive hypotension. - Diuretics: watch electrolyte balance. - ACE inhibitors: assess renal function and blood pressure. - Calcium channel blockers: monitor for additive cardiovascular effects.